FR2770779A1 - Solutions of plasma electrolytes having a lower osmolarity than plasma - Google Patents

Solutions of plasma electrolytes having a lower osmolarity than plasma Download PDF

Info

Publication number
FR2770779A1
FR2770779A1 FR9714073A FR9714073A FR2770779A1 FR 2770779 A1 FR2770779 A1 FR 2770779A1 FR 9714073 A FR9714073 A FR 9714073A FR 9714073 A FR9714073 A FR 9714073A FR 2770779 A1 FR2770779 A1 FR 2770779A1
Authority
FR
France
Prior art keywords
plasma
electrolytes
osmolarity
injection
hypo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9714073A
Other languages
French (fr)
Other versions
FR2770779B1 (en
Inventor
Serge Bernstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9513197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2770779(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to FR9714073A priority Critical patent/FR2770779B1/en
Publication of FR2770779A1 publication Critical patent/FR2770779A1/en
Application granted granted Critical
Publication of FR2770779B1 publication Critical patent/FR2770779B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A hypo-osmolar solution of plasma electrolytes selected from sodium chloride, sodium bicarbonate and electrolytes for injection, the solution having a hypo-osmolarity between 30 and 50% of the osmolarity of plasma. An Independent claim is included for a process for preparing the above solution comprising either (a) diluting 0.9% physiological saline with water for injection; or (b) dissolving the electrolytes in sterile water.

Description

La présente invention consiste en un soluté ayant pour propriété de faire disparaître l'aspect cellulitique, les petits amas graisseux, les défauts de la surface cutanée, les fibroses sous-cutanées et la pilosité de manière définitive.The present invention consists of a solute having the property of eliminating the cellulitic appearance, small fatty deposits, skin surface defects, subcutaneous fibrosis and hair growth permanently.

Jusqu'à aujourd'hui le traitement de l'aspect cellulitique ou des amas graisseux était réalisé soit médicalement, soit chirurgicalement.Until today, the treatment of cellulite or fatty deposits was carried out either medically or surgically.

Les procédés médicaux : crèmes, passage de courant électrique et mésothérapie se révèlent ou inefficaces ou apportent des résultats éphémères (quelques mois).Medical procedures: creams, passage of electric current and mesotherapy prove to be either ineffective or bring ephemeral results (a few months).

Les procédés chirurgicaux représentent un risque chirurgical, une rançon cicatricielle et des résultats parfois désastreux.Surgical procedures represent a surgical risk, a ransom scar and sometimes disastrous results.

En ce qui concerne le traitement des amas graisseux, le soluté faisant l'objet de la présente description est efficace à 100%, d'une manière reproductible et définitive sans les inconvénients ou les risques chirurgicaux.ll est différent des solutions injectées avant les lipo-aspirations car beaucoup plus hypotonique et se suffisant à lui-même.With regard to the treatment of fatty deposits, the solute which is the subject of the present description is 100% effective, in a reproducible and definitive manner without the disadvantages or the surgical risks. It is different from the solutions injected before the lipos -aspirations because much more hypotonic and self-sufficient.

Aucun traitement des fibroses n'existe en dehors de ce procédé.No treatment for fibrosis exists outside of this process.

Les traitements définitifs de la pilosité soit demandent un temps trop long (épilation électrique), soient ne sont pas encore des procédés éprouvés (épilation LASER).The final hair treatments either take too long (electric hair removal) or are not yet proven procedures (LASER hair removal).

Le soluté est hypotonique et hypo-osmolaire par rapport au plasma
L'hypo-osmolarité ou hypotonicité du soluté est comprise entre 30 et 50% de l'osmolarité ou de la tonicité du plasma
Ces propriétés sont obtenues de plusieurs manières, soit par un procédé de dilution, soit par un procédé d'ajout d'électrolytes: - dilution de sérum physiologique à 0,9% en chlorure de sodium dans de l'eau stérile et déminéralisée, connue sous le nom d"'eau pour préparation injectable".The solute is hypotonic and hypo-osmolar compared to plasma
The hypo-osmolarity or hypotonicity of the solute is between 30 and 50% of the osmolarity or the tone of the plasma
These properties are obtained in several ways, either by a dilution process or by a process of adding electrolytes: - dilution of physiological saline to 0.9% in sodium chloride in sterile and demineralized water, known under the name of "water for injection".

- dilution de sérum physiologique à 0,9% en chlorure de sodium associé en partie avec du bicarbonate de sodium dans de l'eau pour préparation injectable, quelle que soit la part de bicarbonate de sodium.- 0.9% physiological saline dilution in sodium chloride associated in part with sodium bicarbonate in water for injection, whatever the proportion of sodium bicarbonate.

- dilution de bicarbonate de sodium dans de l'eau pour préparation injectable.- dilution of sodium bicarbonate in water for injection.

- dilution d'un ensemble d'électrolytes dans de l'eau pour préparation injectable, de manière à obtenir quels que soient ces électrolytes, une hypo-30 osmolarité ou hypotonie comprise entre 30 et 50% de l'osmolarité ou de la tonicité du plasma.dilution of a set of electrolytes in water for injection, so as to obtain, whatever these electrolytes, a hypo-osmolarity or hypotonia of between 30 and 50% of the osmolarity or the tone of the plasma.

Le soluté est injecté en sous-cutané de manière à obtenir un durcissement de la peau au toucher.The solute is injected subcutaneously so as to harden the skin to the touch.

L'injection sera réalisée plus superficiellement dans les indications de traitement de la pilosité, de manière à obtenir un aspect boursouflé de la peau.The injection will be made more superficially in the indications for hair treatment, so as to obtain a puffy appearance of the skin.

Le rythme des injections est d'une tous les 10 à 15 jours sans limite de nombre.The injection rate is one every 10 to 15 days with no limit on the number.

Les résultats sont observables et quantifiables: - amas graisseux: diminution de 1 1 mm de l'épaisseur en 4 séances - pilosité: disparition définitive dès la lère séance - fibrose sous cutanée : disparition progressive, le nombre de séances nécessaire est fonction de l'importance de la fibrose.The results are observable and quantifiable: - fatty deposits: reduction of 1 1 mm in thickness in 4 sessions - hairiness: permanent disappearance from the 1st session - subcutaneous fibrosis: progressive disappearance, the number of sessions required depends on the importance of fibrosis.

Les réactions observées correspondent à celles d'une nécrose tissulaire de faible importance : fièvre de 24 heures et inflammation. The reactions observed correspond to those of a minor tissue necrosis: 24-hour fever and inflammation.

Claims (1)

REVENDICATIONS: -1) Soluté hypo-osmolaire comparativement au plasma d'électrolytes choisis parmi le chlorure de sodium, le bicarbonate de sodium ou des électrolytes destinés à être injectés caractérisés par une hypo-osmolarité comprise entre 30 et 50% de l'osmolarité du plasma. CLAIMS: -1) Hypo-osmolar solute compared to the plasma of electrolytes chosen from sodium chloride, sodium bicarbonate or electrolytes intended for injection characterized by a hypo-osmolarity between 30 and 50% of the osmolarity of plasma. -2) Procédé de préparation selon la revendication 1 caractérisé en ce qu'on effectue une dilution de sérum physiologique à 0,9% en chlorure de sodium dans de l'eau pour préparation injectable.-2) Preparation process according to claim 1 characterized in that one carries out a dilution of physiological saline to 0.9% in sodium chloride in water for injection. -3) Procédé de préparation selon la revendication 1 caractérisé en se qu'on solubilise les électrolytes dans de l'eau stérile.-3) Preparation process according to claim 1 characterized in that the electrolytes are solubilized in sterile water. -4) Utilisation du soluté selon la revendication 1 pour la préparation d'une composition destinée au traitement de la cellulite, des amas graisseux, des fibroses sous cutanées et de l'hyper-pilosité ou hirsutisme. -4) Use of the solute according to claim 1 for the preparation of a composition intended for the treatment of cellulite, fatty deposits, subcutaneous fibrosis and hyper-pilosity or hirsutism.
FR9714073A 1997-11-10 1997-11-10 HYPOTONIC OR HYPOOSMOLAR PLASMA SOLUTE FOR THE TREATMENT OF CELLULITE, FIBROSIS, AND HIRSUTISM Expired - Fee Related FR2770779B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9714073A FR2770779B1 (en) 1997-11-10 1997-11-10 HYPOTONIC OR HYPOOSMOLAR PLASMA SOLUTE FOR THE TREATMENT OF CELLULITE, FIBROSIS, AND HIRSUTISM

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9714073A FR2770779B1 (en) 1997-11-10 1997-11-10 HYPOTONIC OR HYPOOSMOLAR PLASMA SOLUTE FOR THE TREATMENT OF CELLULITE, FIBROSIS, AND HIRSUTISM

Publications (2)

Publication Number Publication Date
FR2770779A1 true FR2770779A1 (en) 1999-05-14
FR2770779B1 FR2770779B1 (en) 2000-07-21

Family

ID=9513197

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9714073A Expired - Fee Related FR2770779B1 (en) 1997-11-10 1997-11-10 HYPOTONIC OR HYPOOSMOLAR PLASMA SOLUTE FOR THE TREATMENT OF CELLULITE, FIBROSIS, AND HIRSUTISM

Country Status (1)

Country Link
FR (1) FR2770779B1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795320A1 (en) * 1999-06-23 2000-12-29 Veronique Bernstein Hypotonic injectable solutions for esthetic treatment and for use in cancer treatment
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
EP1655057A1 (en) 2004-10-27 2006-05-10 Serge Bernstein Water based solutions for the treatment of cellulite
US9808539B2 (en) 2013-03-11 2017-11-07 Endomagnetics Ltd. Hypoosmotic solutions for lymph node detection
US10595957B2 (en) 2015-06-04 2020-03-24 Endomagnetics Ltd Marker materials and forms for magnetic marker localization (MML)
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1507543A4 (en) 2002-05-09 2006-07-26 Cambridgemed Inc A pharmaceutical composition for treatment of wounds containing blood plasma or serum
US9427186B2 (en) 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371522A (en) * 1979-04-25 1983-02-01 Gilbard Jeffrey P Keratoconjunctivitis sicca therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371522A (en) * 1979-04-25 1983-02-01 Gilbard Jeffrey P Keratoconjunctivitis sicca therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUSSIEN R. ET AL: "The tumescent technique revisited", EUROPEAN JOURNAL OF PLASTIC SURGERY, 1996, 19/3 (124-131), GERMANY, XP002059321 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795320A1 (en) * 1999-06-23 2000-12-29 Veronique Bernstein Hypotonic injectable solutions for esthetic treatment and for use in cancer treatment
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
US7255883B2 (en) 2000-06-23 2007-08-14 Healagenics, Inc. Agent for reduction of scar formation by using wound alkalinization
EP1655057A1 (en) 2004-10-27 2006-05-10 Serge Bernstein Water based solutions for the treatment of cellulite
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
US11592501B2 (en) 2009-12-04 2023-02-28 Endomagnetics Ltd. Magnetic probe apparatus
US9808539B2 (en) 2013-03-11 2017-11-07 Endomagnetics Ltd. Hypoosmotic solutions for lymph node detection
US10595957B2 (en) 2015-06-04 2020-03-24 Endomagnetics Ltd Marker materials and forms for magnetic marker localization (MML)
US11504207B2 (en) 2015-06-04 2022-11-22 Endomagnetics Ltd Marker materials and forms for magnetic marker localization (MML)

Also Published As

Publication number Publication date
FR2770779B1 (en) 2000-07-21

Similar Documents

Publication Publication Date Title
Burn A new view of adrenergic nerve fibres, explaining the action of reserpine, bretylium, and guanethidine
FR2770779A1 (en) Solutions of plasma electrolytes having a lower osmolarity than plasma
Apfelberg et al. Histology of port wine stains following argon laser treatment
WO2021004500A1 (en) Transdermal medicament delivery system
WO1990010456A1 (en) Fibroblast growth factor (fgf)-based stabilized compositions
Wilflingseder et al. Magnesium seeds in the treatment of lymph-and haemangiomata: Revival of an old method
Florey et al. Rouget cells and their function
Greve et al. Treating REM syndrome with the pulsed dye laser
Cornbleet Treatment of keloids with hyaluronidase
Balcheva et al. Depigmentation of gingiva
Seccia et al. Treatment of angiomas with sclerosing injection of hydroxypolyethoxydodecan
Westminster et al. Sclerotherapy of Baker’s cyst with imaging confirmation of resolution
KR102096204B1 (en) Localized fat destroying method and hypotonic solution for destroying localized fat
IT9086204A1 (en) METHOD FOR THE TREATMENT OF MALE ERECTIVE IMPOTENCE
Rotter et al. Human saphenous vein in vitro model for studying the action of sclerosing solutions
Goodman Blood transfer: the use of autologous blood as a chromophore and tissue augmentation agent
Lewis Review of intraurethral suppositories and iontophoresis therapy for erectile dysfunction
RU2194537C2 (en) Conservative method for treating urethral strictures
Ovcharenko et al. AUTOLOGOUS PLATELET‐RICH PLASMA: A REVIEW OF SCIENTIFIC ARTICLES ON THE STUDY OF EFFICIENCY IN TREATMENT OF ANDROGENETIC ALOPECIA IN MEN AND WOMEN
RU2200479C2 (en) Method for local introduction of preparations in case of hepatic tumors
EP1570855A1 (en) Use of Botulinum toxin to inhibit hair growth
FR2463617A1 (en) NOVEL SLIMMING COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES AND ESCINE
Mao et al. The biocompatibility of the dermal injection of glycerol in vivo to achieve optical clearing
FR2500305A1 (en) Sperm extract for therapeutic and cosmetic cell revitalisation - by centrifuging to open spermatozoa cells and recovery of supernatant liq.
EP3315130B1 (en) Hyaluronic acid composition including mepivacaine

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130731